Buy CRBP by Oct 27, 2026.

I've spent the last few months digging into Corbus Pharmaceuticals ($CRBP) and it seems the upcoming obesity readout is one of the highest risk/reward catalysts currently in biotech. This is **not financial advice.** There is absolutely a chance the data disappoints. But I think the market is greatly underestimating what positive results could mean. As most know GLP-1s are dominating obesity market currently. But there is another pathway that has also already been proven to work: **CB1 inhibition**. Back in …